About Keros Therapeutics
Keros Therapeutics is a company based in Lexington (United States) founded in 2016.. Keros Therapeutics has raised $90 million across 3 funding rounds from investors including UCSF, GF Securities and Orbimed. The company has 169 employees as of December 31, 2024. Keros Therapeutics offers products and services including KER-050, KER-012, KER-065, Cibotercept, and Elritercept. Keros Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter Lexington, United States
- Employees 169 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Keros Therapeutics, Inc.
-
Annual Revenue
$3.55 M2250.99as on Dec 31, 2024
-
Net Profit
$-187.35 M-22.46as on Dec 31, 2024
-
EBITDA
$-209.6 M-23.93as on Dec 31, 2024
-
Total Equity Funding
$90 M (USD)
in 3 rounds
-
Latest Funding Round
$56 M (USD), Series C
Mar 04, 2020
-
Investors
UCSF
& 9 more
-
Employee Count
169
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Keros Therapeutics
Keros Therapeutics is a publicly listed company on the NASDAQ with ticker symbol KROS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Keros Therapeutics
Keros Therapeutics offers a comprehensive portfolio of products and services, including KER-050, KER-012, KER-065, Cibotercept, and Elritercept. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats ineffective hematopoiesis in blood disorders through TGF-ß modulation
Targets pulmonary arterial hypertension via signaling pathways
Addresses neuromuscular diseases by altering TGF-ß biology
Developed for pulmonary arterial hypertension treatment options
Focuses on hematopoiesis issues in syndromes and disorders
Unlock access to complete
Unlock access to complete
Funding Insights of Keros Therapeutics
Keros Therapeutics has successfully raised a total of $90M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $56 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $56.0M
-
First Round
First Round
(09 Nov 2017)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2020 | Amount | Series C - Keros Therapeutics | Valuation | Foresite Capital , Orbimed | |
| Jan, 2019 | Amount | Series B - Keros Therapeutics | Valuation | Pontifax | |
| Nov, 2017 | Amount | Series A - Keros Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Keros Therapeutics
Keros Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include UCSF, GF Securities and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Keros Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Keros Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Keros Therapeutics Comparisons
Competitors of Keros Therapeutics
Keros Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Drugs for CNS disorders are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Keros Therapeutics
Frequently Asked Questions about Keros Therapeutics
When was Keros Therapeutics founded?
Keros Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Keros Therapeutics located?
Keros Therapeutics is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Is Keros Therapeutics a funded company?
Keros Therapeutics is a funded company, having raised a total of $90M across 3 funding rounds to date. The company's 1st funding round was a Series A of $11M, raised on Nov 09, 2017.
How many employees does Keros Therapeutics have?
As of Dec 31, 2024, the latest employee count at Keros Therapeutics is 169.
What is the annual revenue of Keros Therapeutics?
Annual revenue of Keros Therapeutics is $3.55M as on Dec 31, 2024.
What does Keros Therapeutics do?
Keros Therapeutics was founded in 2016 in Lexington, United States, focusing on the biotechnology sector. Small molecules and biologics are developed for rare neuromuscular and hematologic diseases. The pipeline includes KER-050 in phase II for myelodysplastic syndrome and myelofibrosis; KER-047 for hepcidin-induced anemia and fibrodysplasia ossificans progressiva; and KER-012 for pulmonary arterial hypertension and related bone disorders.
Who are the top competitors of Keros Therapeutics?
Keros Therapeutics's top competitors include Jazz Pharmaceuticals, Biohaven Pharmaceutical and Sana Biotechnology.
What products or services does Keros Therapeutics offer?
Keros Therapeutics offers KER-050, KER-012, KER-065, Cibotercept, and Elritercept.
Is Keros Therapeutics publicly traded?
Yes, Keros Therapeutics is publicly traded on NASDAQ under the ticker symbol KROS.
Who are Keros Therapeutics's investors?
Keros Therapeutics has 10 investors. Key investors include UCSF, GF Securities, Orbimed, Foresite Capital, and Venrock.
What is Keros Therapeutics's ticker symbol?
The ticker symbol of Keros Therapeutics is KROS on NASDAQ.